Early Clinical Drug Development Group

• Early clinical drug development of best-in-class targeted therapies. Determine optimal treatment schedules and identify patient populations who would be most likely to derive benefit from these therapies.
• Innovative clinical trial design for testing novel molecular targeted cancer therapies.
• Link clinical research at our Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch with selected translational research projects led by VHIO investigators.
• Expand our collaboration with different partners in early clinical drug development and translational research (phase I units, academic centers, consortia, and pharmaceutical companies).

Most relevant scientific publications

• Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24;389(8):710-721.
• Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, Ruano I, Attolini CS, Prats N, López-Domínguez JA, Kovatcheva M, Garralda E, Muñoz J, Caron E, Abad M, Gros A, Pietrocola F, Serrano M. Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. Cancer Discov. 2023 Feb 6;13(2):410-431.
• Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Oncology phase I trial design and conduct: time for a change – MDICT Guidelines 2022. Ann Oncol. 2023 Jan;34(1):48-60.
• Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023 Jan 10;41(2):385-394.
• Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Oncology phase I trial design and conduct: time for a change – MDICT Guidelines 2022. Ann Oncol. 2023 Jan;34(1):48-60. Epub 2022 Sep 29.
• Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug;28(8):1640-1645.
• Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium; Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261.
• Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265.
• Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E. Delivering precision oncology to patients with cancer. Nat Med. 2022 Apr;28(4):658-665.
• Villacampa G, Hernando-Calvo A, Berché R, Saavedra O, Marmolejo D, Mirallas O, Braña I, Muñoz-Couselo E, Garralda E, Dienstmann R. Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”. Cancer Treat Rev. 2022 Dec;111:102465.
• Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol. 2022 Oct 6.
• Steeghs N, Hansen AR, Hanna GJ, Garralda E, Park H, Strauss J, Adam M, Campbell G, Carver J, Easton R, Mays K, Skrdla P, Struemper H, Washburn ML, Matheny C, Piha-Paul SA. Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development. Clin Transl Sci. 2022 Nov;15(11):2625-2639.
• Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022 Nov;33(11):1168-1178.
• Borazanci E, Schram AM, Garralda E, Brana I, Vieito Villar M, Spreafico A, Oliva M, Lakhani NJ, Hoffman K, Hallett RM, Maetzel D, Hua F, Hilbert J, Giblin P, Anido J, Kelly A, Vickers PJ, Wasserman R, Seoane J, Siu LL, Hyman DM, Hoff DV, Tabernero J. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO Open. 2022 Aug;7(4):100530.
• Ochsenreither S, Fiedler WM, Del Conte G, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer KF, Saavedra O, Baumeister H, Zurlo A, Garralda A. Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447]. ESMO Open. 2022 Aug;7(4):100549. doi: 10.1016/j.esmoop.2022.100549. Epub 2022 Jul 13. Erratum for: ESMO Open. 2022 Apr;7(2):100447.
• Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium; Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 May;3(5):649. doi: 10.1038/s43018-022-00378-x. Erratum for: Nat Cancer. 2022 Feb;3(2):251-261.
• Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):137-149.
• Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, Macchini M, van den Bent MJ, Del Conte G, de Jonge M, Martín-Soberón MC, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Chang H, Mendez C, Arias Parro M, Wei X, Nikolova Z, Sepulveda JM. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2022 Oct 28;4(1):vdac146.
• Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct;10(10):e004235.
• Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. ESMO Open. 2022 Oct;7(5):100562.
• Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, Freimoser-Grundschober A, Cuartas I, Martínez-Moreno A, Martínez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia-Reyes X, Fahrni L, Pöschinger T, Steinhart V, Richard M, Briner S, Mueller J, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, González J, Nuciforo P, Carles J, Vieito M, Tabernero J, Umaña P, Seoane J. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther. 2022 Oct 7;21(10):1499-1509.
• Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan;10(1):e46-e58. Epub 2022 Nov 10.
• Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
• Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, Kristeleit R, Sarker D, Arkenau T, Roxburgh P, Walter HS, Blagden S, Anthoney A, Klencke BJ, Kowalski MM, Banerji U. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clin Cancer Res. 2023 Jan 17;29(2):331-340.
• Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 Jul 1;28(13):2762-2770.
• Lorini L, Perri F, Vecchio S, Belgioia L, Vinches M, Brana I, Elad S, Bossi P. Confounding factors in the assessment of oral mucositis in head and neck cancer. Support Care Cancer. 2022 Oct;30(10):8455-8463.
• Sabaté Gallego M, Pérez Esquirol E, Garcia Doladé N, Vidal Guitart X, Carreras Soler MJ, Farriols Danés A, Felip E, Braña I, Carles Galceran J, Morales Barrera R, Muñoz-Couselo E, Agustí Escasany A. Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice. Front Med (Lausanne). 2022 Aug 22;9:891179.
• Boni V, Pistilli B, Braña I, Shapiro GI, Trigo J, Moreno V, Castellano D, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Antón A, Paredes A, Huidobro G, Subbiah V. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open. 2022 Oct;7(5):100571.
• Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol. 2022 May;128:105815.
• Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022 Jul 20;40(21):2321-2332.
• Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2023 Feb 1;41(4):790-802.
• Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022 Nov;33(11):1168-1178.
• Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O’Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer. 2022 Mar 15;150(6):993-1006.
• Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol. 2022 Oct 6. doi: 10.2217/fon-2022-0660.
• Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, Macchini M, van den Bent MJ, Del Conte G, de Jonge M, Martín-Soberón MC, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Chang H, Mendez C, Arias Parro M, Wei X, Nikolova Z, Sepulveda JM. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2022 Oct 28;4(1):vdac146.
• Ros J, Saoudi N, Salvà F, Baraibar I, Alonso G, Tabernero J, Elez E. Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. Expert Opin Investig Drugs. 2022 Mar;31(3):235-247.
• Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L, Shapiro GI, Siu LL, Hansen AR. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Jun 1;28(11):2257-2269.
• Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct;10(10):e004235.
• Massard C, Cassier PA, Azaro A, Anderson B, Yuen E, Yu D, Oakley G 3rd, Benhadji KA, Pant S. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol. 2022 Oct;90(4):335-344.
• Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol. 2022 Feb;6:e2100267.
• Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E. Delivering precision oncology to patients with cancer. Nat Med. 2022 Apr;28(4):658-665.
• Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug;28(8):1640-1645.
• Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium; Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261.
• Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265.
• Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. Eur J Cancer. 2021 Sep;155:168-178.
• Matos I, Garralda E. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy. JAMA Oncol. 2021 Jan 1;7(1):136-137.
• Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Jun 10;39(17):1856-1864.
• Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119.
• Rodon, J., Argilés, G., Connolly, R.M., Vaishampayan, Ulka, de Jonge, Maja, Garralda, Elena, Giannakis, Marios, Smith, David C., Dobson, Jason R., McLaughlin, Margaret E., Seroutou, Abdelkader, Ji, Yan, Morawiak Jennifer, Moody Susan E., Janku Filip. “Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours” Br J Cancer (3 May 2021). https://doi.org/10.1038/s41416-021-01389-8
• P. Garrido, A. A. Adjei , J. Bajpai , S. Banerjee , A. S. Berghoff , S. P. Choo , E. Felip , A. J. S. Furness , E. Garralda , J. Haanen, A. Letsch, H. Linardou, S. Peters, C. Sessa, J. Tabernero, J. Tsang, J. C-.H. Yang1 & M. C. Garassino. “Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey”. May 25, 2021.DOI:https://doi.org/10.1016/j.esmoop.2021.10013
• Vieito M., Gardeazabal I., Matos I., Garralda E. (2020) “Development of Pharmacodynamic Biomarkers for Phase I Trials” In: Yap T.A., Rodon J., Hong D.S. (eds) Phase I Oncology Drug Development. Springer, Cham. https://doi.org/10.1007/978-3-030-47682-3_9
• Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, Guillermo Villacampa, Maria V. Raciti, Jaid Landa, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa-de-Olza, Cinta Hierro, Joaquin Mateo, Macarena Gonzalez, Rafael Morales-Barrera, Cristina Suarez, Jordi Rodon, Elena Elez, Irene Braña, Eva Muñoz-Couselo, Ana Oaknin, Roberta Fasani, Paolo Nuciforo, Debora Gil, Carlota Rubio-Perez, Joan Seoane, Enriqueta Felip, Manuel Escobar, Josep Tabernero, Joan Carles, Rodrigo Dienstmann, Elena Garralda, Raquel Perez-Lopez. “A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors.” Radiology 2021. 299:1, 109-119. https://doi.org/10.1148/radiol.2021200928
• Matos I, Garralda E. “Clarification of Definitions of Hyperprogressive Disease During Immunotherapy”. JAMA Oncol. 2021;7(1):136–137. doi:10.1001/jamaoncol.2020.5582
• Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J,Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020 Jul;26(7):992-994.
• Matos I, Martin-Liberal J, García- Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Braña I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Elez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodón J, Tabernero J,Dienstmann R, Perez-Lopez R, Garralda E. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. Clin Cancer Res. 2020 Apr 15;26(8):1846-1855.
• Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O,Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824.
• van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I,Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 May;26(5):665-671.
• Rodon J, Soria, JC, Berger R, Miller, W H, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, BressonC, Martini, JF, Raynaud, J, Mendelsohn, J, Batist, G, Onn, A, Tabernero, J, Richard L Schilsky, RL, Lazar, V, Lee, JJ, Kurzrock, R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 May;25(5):751-758.
• Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019 Jun 11;10(1):2416.
• Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E. Agnostic-Histology Approval of new drugs in Oncology: are we already there? Clin Cancer Res. 2019 Jun 1;25(11):3210-3219.
• Garralda E, Dienstmann R, Piris A, Braña I, Rodon J, Tabernero J. New clinical trial designs in the era of Precision Medicine. Mol Oncol. 2019 Mar;13(3):549-557
• Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E.Agnostic-Histology Approval of new drugs in Oncology: are we already there? Clin Cancer Res. 2019 Jan 22. pii: clincanres.3694.2018. doi: 10.1158/1078-0432.CCR-18-3694. [Epub ahead of print]
• Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Early-drug development in the era of immuno-oncology: are we ready to face the challenges? Ann Oncol. 2018 Aug 1;29(8):1727-1740.
• Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 Jul;8(7):836-849.
• Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194.
• Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351.
• Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599.
• Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 1;35(34):3823-3829.
• Hierro C, Alsina M, Sánchez M, Serra V, Rodon J, Tabernero J. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? Ann Oncol. 2017 Jun 1;28(6):1207-1216.
• Martin- Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev. 2017 Mar;54:74-86.
• Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res. 2016 Oct 15;22(20):5049-5057.
• Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
• Dienstmann R, Rodón J, Tabernero J. Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. Mol Oncol 2015 May; 9(5): 940-50
• Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2015 Apr; 33(2): 357-70
• Hierro C, Rodón J, Tabernero J. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin. Oncol. 2015 Dec; 42(6): 801-19
• Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martínez-Ricarte F, Rodón J, Auger C, Salas-Puig J, Santamarina E, Martínez-Sáez E. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg 2015 Dec; 139: 166-71
• Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Pérez-García J, Galván P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015 Apr; 7(283): 283ra51
• Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodón J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin. Cancer Res. 2015 Feb; 21(3): 585-93
• Rodón J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res. 2015 Feb; 21(3): 553-60
• De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839

All publications

• Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24;389(8):710-721.
• Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, Ruano I, Attolini CS, Prats N, López-Domínguez JA, Kovatcheva M, Garralda E, Muñoz J, Caron E, Abad M, Gros A, Pietrocola F, Serrano M. Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. Cancer Discov. 2023 Feb 6;13(2):410-431.
• Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Oncology phase I trial design and conduct: time for a change – MDICT Guidelines 2022. Ann Oncol. 2023 Jan;34(1):48-60.
• Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023 Jan 10;41(2):385-394.
• Rodon J, Argilés G, Connolly RM, Vaishampayan U, de Jonge M, Garralda E, Giannakis M, Smith DC, Dobson JR, McLaughlin ME, Seroutou A, Ji Y, Morawiak J, Moody SE, Janku F. Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br J Cancer. 2021 Jul;125(1):28-37.
• Wright SCE, Vasilevski N, Serra V, Rodon J, Eichhorn PJA. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers (Basel). 2021 Mar 26;13(7):1538.
• Lorini L, Bescós Atín C, Thavaraj S, Müller-Richter U, Alberola Ferranti M, Pamias Romero J, Sáez Barba M, de Pablo García-Cuenca A, Braña García I, Bossi P, Nuciforo P, Simonetti S. Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. Cancers (Basel). 2021 Jul 23;13(15):3696.
• Luque R, Benavides M, Del Barco S, Egaña L, García-Gómez J, Martínez-García M, Pérez-Segura P, Pineda E, Sepúlveda JM, Vieito M. SEOM clinical guideline for management of adult medulloblastoma (2020). Clin Transl Oncol. 2021 May;23(5):940-947.
• Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6666-6676.
• Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):137-149.
• Oberoi HK, Garralda E. Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates. Clin Cancer Res. 2021 Aug 15;27(16):4459-4461.
• Garrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, Felip E, Furness AJS, Garralda E, Haanen J, Letsch A, Linardou H, Peters S, Sessa C, Tabernero J, Tsang J, Yang JC, Garassino MC. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 Jun;6(3):100131.
• Vidal L, Victoria I, Gaba L, Martín MG, Brunet M, Colom H, Cortal M, Gómez-Ferrería M, Yeste-Velasco M, Perez A, Rodon J, Sohal DPS, Lizcano JM, Domènech C, Alfón J, Gascón P. A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. Eur J Cancer. 2021 Mar;146:87-94.
• Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. Eur J Cancer. 2021 Sep;155:168-178.
• Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, Nuciforo P, Canes J, Paré L, Dueñas M, Vidal M, Cejalvo JM, Perelló A, Llommbard-Cussac A, Dorca J, Montaño A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 2021 Nov 4;11:744112.
• Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O’Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer. 2022 Mar 15;150(6):993-1006.
• Piha-Paul SA, Azaro A, Arkenau HT, Oh DY, Galsky MD, Pal SK, Hamada K, He Y, Yamamiya I, Benhadji KA, Hollebecque A. A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Invest New Drugs. 2021 Oct;39(5):1324-1334.
• Azaro A, Massard C, Tap WD, Cassier PA, Merchan J, Italiano A, Anderson B, Yuen E, Yu D, Oakley G 3rd, Benhadji KA, Pant S. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Invest New Drugs. 2021 Aug;39(4):1089-1098.
• Azaro A, Baldini C, Rodon J, Soria JC, Yuen E, Lithio A, Oakley G, Benhadji KA, Massard C. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. Invest New Drugs. 2021 Feb;39(1):193-201.
• How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 Jun;39(3):829-835.
• Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, Planchard D, Balleyguier C, Besse B, Mezquita L, Lassau N, Caramella C. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. JAMA Oncol. 2020 Jul 1;6(7):1039-1046.
• Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. J Clin Oncol. 2021 Jan 10;39(2):145-154.
• Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Jun 10;39(17):1856-1864.
• Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501.
• Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul;22(7):959-969.
• Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507-2543.
• Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. NPJ Precis Oncol. 2021 Apr 28;5(1):33.
• Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos KP, Crittenden M, Formenti S, Giralt J, Garrido P, Soria A, Hervás-Morón A, Mohan KK, Fury M, Lowy I, Mathias M, Feng M, Li J, Stankevich E. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist. 2021 Sep;26(9):e1508-e1513.
• Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119.
• Actively personalized vaccination trial for newly diagnosed glioblastoma. Hilf N; Kuttruff-Coqui S; Frenzel K; Bukur V; Stevanovic S; Gouttefangeas C; Platten M; Tabatabai G; Dutoit V; van der Burg SH; Thor Straten P; Martínez-Ricarte F; Ponsati B; Okada H; Lassen U; Admon A; Ottensmeier CH; Ulges A; Kreiter S; von Deimling A; Skardelly M; Migliorini D; Kroep JR; Idorn M; Rodon J; et al… 2019. Nature. 565(7738): 240 – 245.
• Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I. 2019. Lancet Oncol. 20(8): 1109 – 1123.
• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Rodon J; Soria JC; Berger R; Miller WH; Rubin E; Kugel A; Tsimberidou A; Saintigny P; Ackerstein A; Braña I; Loriot Y; Afshar M; Miller V; Wunder F; Bresson C; Martini JF; Raynaud J; Mendelsohn J; Batist G; Onn A; Tabernero J; Schilsky RL; Lazar V; Lee JJ; Kurzrock R. 2019. Nat Med. 25(5): 751 – 751.
• Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial.Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS. 2019. JAMA Oncol. 5(2): e184475.
• Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial.Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J. 2019. JAMA Oncol. 5(2): 195 – 203.
  • Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. Ros J; Matos I; Martin-Liberal J. 2019. Ann Oncol. 30(7): 1173 – 1177.
• Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Hyun Cheol Chung; Sarina A. Piha-Paul; Jose Lopez-Martin; Jan H.M. Schellens; Steven Kao; Wilson H. Miller; Jean-Pierre Delord; Bo Gao; David Planchard; Maya Gottfried; Alona Zer; Shadia I. Jalal; Nicolas Penel; Janice M. Mehnert; Ignacio Matos; Jaafar Bennouna; Dong-Wan Kim; Lei Xu; Suba Krishnan; Kevin Norwood; Patrick A. Ott. 2019. J Thorac Oncol.
• LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Pascual-García M; Bonfill-Teixidor E; Planas-Rigol E; Rubio-Perez C; Iurlaro R; Arias A; Cuartas I;Sala-Hojman A; Escudero L; Martínez-Ricarte F; Huber-Ruano I; Nuciforo P; Pedrosa L; Marques C; Braña I; Garralda E; Vieito M; Squatrito M; Pineda E; Graus F; Espejo C; Sahuquillo J; Tabernero J; Seoane J. 2019. Nat Commun. 10: 2416 – 2416.
• A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Atrafi F; Groen HJM; Byers LA; Garralda E; Lolkema MP; Sangha RS; Viteri S; Chae YK; Camidge DR; Gabrail NY; Hu B; Tian T; Nuthalapati S; Hoening E; He L; Komarnitsky P; Calles A. 2019. Clin Cancer Res. 25(2): 496 – 505.
• A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J. 2019. Clin Cancer Res. 25(9): 2699 – 2707.
• Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E. 2019. Clin Cancer Res.25(11): 3210 – 3219.
• Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Bahleda R; Italiano A; Hierro C; Mita AC; Cervantes A; Chan N; Awad MM; Calvo E; Moreno V; Govindan R; Spira AI; Gonzalez MD; Zhong B; Santiago-Walker AE; Poggesi I; Parekh T; Xie H; Infante JR; Tabernero J. 2019. Clin Cancer Res. 25(16): 4888 – 4897.
• Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Jung KH; LoRusso PM; Burris HA; Gordon MS; Bang YJ; Hellmann MD; Cervantes A; Ochoa de Olza M; Marabelle A; Hodi FS; Ahn MJ; Emens LA; Barlesi F; Hamid O; Calvo E; McDermott DF; Soliman H; Rhee I; Lin R; Pourmohamad T; Suchomel J; Tsuhako A; Morrissey KM; Mahrus S; Morley R; Pirzkall A; Davis SL. 2019. Clin Cancer Res. 25(11): 3220 – 3228.
• Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >= 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R. 2019. Eur J Cancer.107: 142 – 152.
• New clinical trial designs in the era of precision medicine. Garralda E; Dienstmann R; Piris A; Braña I; Rodon J; Tabernero J. 2019. Mol Oncol.13(3): 549 – 557.
• Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Bellet M; Ahmad F; Villanueva R; Valdivia C; Palomino-Doza J; Ruiz A; Gonzàlez X; Adrover E; Azaro A; Valls-Margarit M; Parra JL; Aguilar J; Vidal M; Martín A; Gavilá J; Escrivá-de-Romaní S; Perelló A; Hernando C; Lahuerta A; Zamora P; Reyes V; Alcalde M; Masanas H; Céliz P; Ruíz I; Gil M; Seguí MÀ; de la Peña L. 2019. Ther Adv Med Oncol. 11: 1758835919833867.
• Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P. 2019. Br J Cancer. 121(7): 537 – 544.
• Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R; EVERLAR study investigators. 2019. Oncologist. 24(1): 38 – 46.
• Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. Martin-Liberal J; Pérez E; García Del Muro X. 2019. Expert Opin Investig Drugs. 28(1): 39 – 50.
• Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer – prospects from phase II clinical trials. Matos I; Noguerido A; Ros J; Mulet N; Argilés G; Elez É; Tabernero J. 2019. Expert Opin Investig Drugs. 28(5): 463 – 471.
• Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. Cubillo A; Álvarez-Gallego R; Muñoz M; Pond G; Perea S; Sánchez G; Martin M; Rodríguez-Pascual J; Garralda E; Vega E; de Vicente E; Quijano Y; Muñoz C; Ugidos L; Toledo RA; Hidalgo M. 2019. Am J Clin Oncol. 42(1): 56 – 59.
• Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D. 2019. Invest New Drugs. 37(2): 271 – 281.
• Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Sankhala K; Takimoto CH; Mita AC; Xiong H; Rodón J; Mehrvarz Sarshekeh A; Burns K; Iizuka K; Kopetz S. 2019. Invest New Drugs. 37(1): 76 – 86.
• KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Kato K; Shah MA; Enzinger P; Bennouna J; Shen L; Adenis A; Sun JM; Cho BC; Özgüroglu M; Kojima T; Kostorov V; Hierro C; Zhu Y; McLean LA; Shah S; Doi T. 2019. Future Oncol. 15(10): 1057 – 1066.
• RNF43 – and NOTCH1 -Mutated Chemotherapy and Anti–EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. Aguilar, Susana; Santos, Cristina; Martini, Giulia; Argiles, Guillem; Azaro, Analia; Garralda, Elena; Tabernero, Josep; Nuciforo, Paolo;Vivancos, Ana; Dienstmann, Rodrigo. 2019. JCO Precis Oncol. 1 – 3.
• PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma..Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG. 2018. N Engl J Med. 379: 341-351.
• HER kinase inhibition in patients with HER2- and HER3-mutant cancers..Hyman DM; Piha-Paul SA; Won H; Rodon J; Saura C; Shapiro GI; Juric D; Quinn DI; Moreno V; Doger B; Mayer IA; Boni V; Calvo E; Loi S; Lockhart AC; Erinjeri JP; Scaltriti M; Ulaner GA; Patel J; Tang J; Beer H; Selcuklu SD; Hanrahan AJ; Bouvier N; Melcer M; Murali R; Schram AM; Smyth LM; Jhaveri K; Li BT; Drilon A; Harding JJ; Iyer G; Taylor BS; Berger MF; Cutler RE; Xu F; Butturini A; Eli LD; Mann G; Farrell C; Lalani AS; Bryce RP; Arteaga CL; Meric-Bernstam F; Baselga J; Solit DB. 2018. Nature. 554: 189-194.
• Encorafenib plus binimetinib: an embarrassment of riches..Martin-Liberal J. 2018. Lancet Oncol. 19: 1263-1264.
• Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J. 2018. J Clin Oncol. 36: 1291-0.
• Precision Targeted Therapy with BLU-667 for RET -Driven Cancers..Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK. 2018. Cancer Discov. 8: 836-849.
• Early evolutionary divergence between papillary and anaplastic thyroid cancers..Capdevila J; Mayor R; Mancuso FF; Iglesias C; Caratù G; Matos I; Zafón C; Hernando J; Petit A; Nuciforo P; Cameselle-Teijeiro JM; Álvarez C; Recio JA; Tabernero J; Matias-Guiu X; Vivancos A; Seoane J. 2018. Ann Oncol. 29: 1454-1460.
• Early-drug development in the era of immuno-oncology: are we ready to face the challenges?.Ochoa de Olza M; Oliva M; Hierro C; Matos I; Martin-Liberal J; Garralda E. 2018. Ann Oncol. 29: 1727-1740.
• First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer..Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J. 2018. Ann Oncol. 29: 1911-1917.
• Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial..Colevas AD; Bahleda R; Braiteh F; Balmanoukian A; Brana I; Chau NG; Sarkar I; Molinero L; Grossman W; Kabbinavar F; Fassò M; O’Hear C; Powderly J. 2018. Ann Oncol. 29: 2247-2253.
• The European Society for Medical Oncology (ESMO) Precision Medicine Glossary..Yates LR; Seoane J; Le Tourneau C; Siu LL; Marais R; Michiels S; Soria JC; Campbell P; Normanno N; Scarpa A; Reis-Filho JS; Rodon J; Swanton C; Andre F. 2018. Ann Oncol. 29: 30-35.
• Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies..Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero A; Albarran MI; Baños N; Duran Y; Bonilla V; Sarno F; Camacho Artacho M; Sánchez-Pérez T; Perea S; Alvarez R; De Martino Rodriguez A; Lietha D; Blanco-Aparicio C; Cubillo A; Dominguez O; Martínez-Torrecuadrada J; Hidalgo M. 2018. Clin Cancer Res. 24: 3550-3559.
• First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.Hidalgo M; Martinez-Garcia M; Le Tourneau C; Massard C; Garralda E; Boni V; Taus A; Albanell J; Sablin MP; Alt M; Bahleda R; Varga A; Boetsch C; Franjkovic I; Heil F; Lahr A; Lechner K; Morel A; Nayak TK; Rossomanno S; Smart K; Stubenrauch KG; Krieter O. 2018. Clin Cancer Res. 24: 1536-1545.
• Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid..Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; Lopez-Bigas N; Ramón Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J. 2018. Clin Cancer Res. 24: 2812-2819.
• Precision Oncology Decision Support: Current Approaches and Strategies for the Future..Kurnit KC; Dumbrava EEI; Litzenburger B; Khotskaya YB; Johnson AM; Yap TA; Rodon J; Zeng J; Shufean MA; Bailey AM; Sánchez NS; Holla V; Mendelsohn J; Shaw KM; Bernstam EV; Mills GB; Meric-Bernstam F. 2018. Clin Cancer Res. 24: 2719-2731.
• Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations..Tamborero, David; Rubio-Perez, Carlota; Deu-Pons, Jordi; Schroeder, Michael P.; Vivancos, Ana; Rovira, Ana; Tusquets, Ignasi; Albanell, Joan; Rodon, Jordi; Tabernero, Josep; de Torres, Carmen; Dienstmann, Rodrigo; Gonzalez-Perez, Abel; Lopez-Bigas, Nuria. 2018. Genome Med. 10: 25-0.
• Precision oncology: East meets West. Subbiah V; Rodon J; Yap TA. 2018. INT J CANCER. 142: 1734-1737.
• First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanovic N; Cmiljanovic V; Stumm M; Dimitrijevic S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R. 2018. Eur J Cancer. 96: 6-16.
• Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours..Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C. 2018. Eur J Cancer. 103: 88-97.
• Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI. 2018. Oncologist. 23: 401-0.
• Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)..Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I. 2018. Oncologist.
• Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma..Shraibman B; Barnea E; Melamed Kadosh D; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; Von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A. 2018. MOL CELL PROTEOMICS. 17: 2132-2145.
• A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors..Rodon J; Curigliano G; Delord JP; Harb W; Azaro A; Han Y; Wilke C; Donnet V; Sellami D; Beck T. 2018. Oncotarget. 9: 31709-31718.
• Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study..Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X. 2018. Target Oncol. 13: 81-87.
• Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.Calvo E; Azaro A; Rodon J; Dirix L; Huizing M; Senecal FM; LoRusso P; Yee L; Poggesi I; de Jong J; Triantos S; Park YC; Knoblauch RE; Parekh TV; Demetri GD; von Mehren M. 2018. Invest New Drugs. 36: 476-486.
• Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer..Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J. 2018. Expert Opin Pharmacother. 19: 623-629.
• The safety of ramucirumab for the treatment of colorectal cancer..Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J. 2018. EXPERT OPIN DRUG SAF. 17: 945-951.
  • Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma..Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O’Hear C; Grossman W; Baehring J. 2018. J Neurooncol. 140: 317-328.
• The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs..Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG. 2018. Trials. 19: 505-0.
• Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey..Banerjee S; Dafni U; Allen T; Arnold D; Curigliano G; Garralda E; Garassino MC; Haanen J; Hofstädter-Thalmann E; Robert C; Sessa C; Tsourti Z; Zygoura P; Peters S. 2018. ESMO Open.
• Report on the status of women occupying leadership roles in oncology..Hofstädter-Thalmann E; Dafni U; Allen T; Arnold D; Banerjee S; Curigliano G; Garralda E; Garassino MC; Haanen J; Robert C; Sessa C; Tsourti Z; Zygoura P; Peters S. 2018. ESMO Open.
• Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer..Meric-Bernstam F; Zheng X; Shariati M; Damodaran S; Wathoo C; Brusco L; Demirhan ME; Tapia C; Eterovic AK; Basho RK; Ueno NT; Janku F; Sahin A; Rodon J; Broaddus R; Kim TB; Mendelsohn J; Mills Shaw KR; Tripathy D; Mills GB; Chen K. 2018. JCO Precis Oncol.
• Improving the armamentarium of PI3K inhibitors with isoform-selective agents: A new light in the darkness. Rodon J; Tabernero J.2017.Cancer Discov.7: 666-669. IF:20,011
• Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: A post hoc analysis of the Mainsail study. de Morrée ES; Vogelzang NJ; Petrylak DP; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; Ochoa de Olza M; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; Li JS; de Wit R.2017.JAMA Oncol.3: 68-75. IF:16,559
• Targeting the fibroblast growth factor receptor 2 in gastric cancer: Promise or pitfall?.Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J. 2017.Ann Oncol.28: 1207-1216. IF:11,855
• The expanding role of immunotherapy.Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J. 2017.Cancer Treat Rev.54: 74-86. IF:8,589
• Clinical research in small genomically stratified patient populations. Martin-Liberal J; Rodon J. 2017.Eur J Cancer.80: 73-82. IF:6,029
• First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.Rodon J; Postel-Vinay S; Hollebecque A; Nuciforo P; Azaro A; Cattan V; Marfai L; Sudey I; Brendel K; Delmas A; Malasse S; Soria JC.2017.Eur J Cancer.81: 142-150. IF:6,029
• A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification..Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F. 2017.Eur J Cancer.87: 131-139. IF:6,029
• Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D.2017.Eur J Cancer.87: 30-37. IF:6,029
• Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights.Dienstmann R; Elez E; Argiles G; Matos I; Sanz-Garcia E; Ortiz C; Macarulla T; Capdevila J; Alsina M; Sauri T; Verdaguer H; Vilaro M; Ruiz-Pace F; Viaplana C; Garcia A; Landolfi S; Palmer HG; Nuciforo P; Rodon J; Vivancos A; Tabernero J. 2017.Mol Oncol.11: 1263-1272. IF:5,314
• Unveiling changes in the landscape of patient populations in cancer early drug development. Hierro C; Azaro A; Argilés G; Elez E; Gómez P; Carles J; Rodon J. 2017.Oncotarget.8: 14158-14172. IF:5,168
• Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M. 2017.Oncotarget.8: 35289-35300. IF:5,168
• Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients. León-Mateos L; Casas H; Abalo A; Vieito M; Abreu M; Anido U; Gómez-Tato A; López R; Abal M; Muinelo-Romay L. 2017.Oncotarget.8: 54708-54721. IF:5,168
• Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. Brana, Irene; Nhu-An Pham; Kim, Lucia; Sakashita, Shingo; Li, Ming; Ng, Christine; Wang, Yuhui; Loparco, Peter; Sierra, Rafael; Wang, Lisa; Clarke, Blaise A.; Neel, Benjamin G.; Siu, Lillian L.; Tsao, Ming-Sound. 2017.Oncotarget.8: 84659-84670. IF:5,168
• Development of Molecularly Driven Targeted Combination Strategies. Yap, Timothy A.; Rodon, Jordi. 2017.Oncologist.22: 1421-1423. IF:4,962
• Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).Capdevila J; Trigo JM; Aller J; Manzano JL; Garcia-Adrian S; Zafon C; Reig O; Bohn U; Ramon Y Cajal T; Duran M; Gonzalez-Astorga B; Lopez-Alfonso A; Medina J; Porras I; Reina JJ; Palacios N; Grande E; Cillan E; Matos I; Grau JJ. 2017.Eur J Endocrinol.177: 309-317. IF:4,101
• Immuno-Oncology: The Third Paradigm in Early Drug Development. Martin-Liberal J; Hierro C; Ochoa de Olza M; Rodon J. 2017.Target Oncol.12: 125-138. IF:3,438
• A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Wainberg ZA; Alsina M; Soares HP; Braña I; Britten CD; Del Conte G; Ezeh P; Houk B; Kern KA; Leong S; Pathan N; Pierce KJ; Siu LL; Vermette J; Tabernero J. 2017.Target Oncol.12: 775-785. IF:3,438
• The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Amair-Pinedo F; Matos I; Saurí T; Hernando J; Capdevila J. 2017.Target Oncol.12: 757-774. IF:3,438
• Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine..Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W. 2017.INT J MOL SCI.. IF:3,226
• Epileptic features and survival in glioblastomas presenting with seizures. Toledo M; Sarria-Estrada S; Quintana M; Maldonado X; Martinez-Ricarte F; Rodon J; Auger C; Aizpurua M; Salas-Puig J; Santamarina E; Martinez-Saez E. 2017.EPILEPSY RES.130: 1-6. IF:2,367
• Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience.Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J. 2017.FUTURE ONCOL.13: 615-624. IF:2,131
• Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients. Hierro, Cinta; Alsina, Maria; Tabernero, Josep. 2017.TRANSL CANCER RES.6: 1035-1039. IF:1,167
• Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R. A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors. Clin Cancer Res. 2017 Mar 6. pii: clincanres.2796.2016. doi: 10.1158/1078-0432.CCR-16-2796.
• Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017 Feb 7. doi: 10.1093/annonc/mdx008. [Epub ahead of print]
• Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov. 2017 Jan;7(1):102-113. doi:10.1158/2159-8290.CD-16-0512.
• Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J. Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget. 2016 Nov 9. doi: 10.18632/oncotarget.13258. [Epub ahead of print] Review.
• Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452-63. doi: 10.1016/S1470-2045(15)00614-2.
• Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi:10.1158/1078-0432.CCR-15-2400.
• Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J. First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.Target Oncol. 2016 Apr;11(2):149-56. doi: 10.1007/s11523-015-0381-x.
• Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev. 2017 Mar;54:74-86. doi: 10.1016/j.ctrv.2017.01.008. Review.
• Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Review.
• Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol. 2016 Dec 20. [Epub ahead of print] PubMed PMID: 27995439.
• Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. Drugs Context. 2016 Dec 2;5:212303.
• Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RH, Clot PF, Wack C, Shen L, de Jonge MJ. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol. 2016 Dec;78(6):1185-1197.
• Cassel JB, Del Fabbro E, Arkenau T, Higginson IJ, Hurst S, Jansen LA, Poklepovic A, Rid A, Rodón J, Strasser F, Miller FG. Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy? J Pain Symptom Manage. 2016 Sep;52(3):437-45. doi: 10.1016/j.jpainsymman.2016.02.014.
• Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res. 2016 Oct 15;22(20):5049-5057. PubMed PMID: 27178743.
• Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol. 2016 Aug;27(8):1443-8. doi: 10.1093/annonc/mdw192
• Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 Apr;15(4):533-47. doi: 10.1158/1535-7163.MCT-15-0643. Review.
• Batchelor T, Rodon J, Ahluwalia M. Principles of pharmacotherapy. Handb Clin Neurol. 2016;134:149-62. doi: 10.1016/B978-0-12-802997-8.00009-8.
• Ciardiello F, Adams R, Tabernero J, Seufferlein T, Taieb J, Moiseyenko V, Ma B, Lopez G, Vansteenkiste JF, Esser R, Tejpar S. Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist. 2016 Mar;21(3):292-300. doi: 10.1634/theoncologist.2015-0279.
• Alsina M, Moehler M, Hierro C, Guardeño R, Tabernero J. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Target Oncol. 2016 Aug;11(4):469-77. doi: 10.1007/s11523-016-0421-1.
• Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081.
• Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
• Dienstmann R, Rodón J, Tabernero J. Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. Mol Oncol 2015 May; 9(5): 940-50
• Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2015 Apr; 33(2): 357-70
• Hierro C, Rodón J, Tabernero J. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin. Oncol. 2015 Dec; 42(6): 801-19
• Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martínez-Ricarte F, Rodón J, Auger C, Salas-Puig J, Santamarina E, Martínez-Sáez E. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg 2015 Dec; 139: 166-71
• Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Pérez-García J, Galván P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015 Apr; 7(283): 283ra51
• Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodón J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin. Cancer Res. 2015 Feb; 21(3): 585-93
• Rodón J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res. 2015 Feb; 21(3): 553-60
• De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
• Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
• Spreafico A, Delord JP, De Mattos-Arruda L, Bergé Y, Rodón J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br. J. Cancer 2015 Feb; 112(4): 650-9
• Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodón J, Peddareddigari V, Luo FR, Soria JC. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J. Clin. Oncol. 2015 Oct; 33(30): 3401-8
• De Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015 Apr; 12(4): 197-212
• Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodón J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015 Apr; 27(4): 533-46
• Zeron-Medina J, Ochoa de Olza M, Braña I, Rodón J. The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Semin. Oncol. 2015 Dec; 42(6): 775-87
• Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodón J, Lahn MF. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Oncol Lett 2015 Jun; 9(6): 2442-2448
• Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodón J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget 2015 Jun; 6(16): 14139-52
• Rodón J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann. Oncol. 2015 Aug; 26(8): 1791-8
• Azaro A, Rodón J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs 2015 Jun; 33(3): 710-9
• Dienstmann R, Rodón J, Prat A, Pérez-García J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014 Mar; 25(3): 552-63
• Shapiro GI, Rodón J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 2014 Jan; 20(1): 233-45
• Dienstmann R, Rodón J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther. 2014 May; 13(5): 1021-31
• Bellmunt J, Suárez C, Gallardo E, Rodón J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist 2014 Sep; 19(9): 917-8
• Rodón J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin. Cancer Res. 2014 Apr; 20(7): 1900-9
• Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodón J, Kurzrock R, Subbiah V. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med 2014 Dec; 18(101): 331-9
• Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodón J, Kurzrock R, Subbiah V. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med 2014 Dec; 18(101): 323-30
• Rodón J, Braña I, Siu LL, de Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014 Aug; 32(4): 670-81
• Mahalingam D, Malik L, Beeram M, Rodón J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother. Pharmacol. 2014 Jul; 74(1): 77-84
• Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
• Rodón J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013 Mar; 10(3): 143-53
• Dienstmann R, Rodón J, Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol 2013 May; 25(3): 305-12
• Dienstmann R, Rodón J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J. Clin. Oncol. 2013 May; 31(15): 1874-84
• De Mattos-Arruda L, Rodón J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist 2013; 18(11): 1180-8
• Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodón J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013 Jul; 5(196): 196ra99
• Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J, Rodriguez O, Calvo MT, Aura C, Diez O, Rubio IT, Pérez J, Rodón J, Cortes J, Ellisen LW, Scaltriti M, Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012 Nov; 2(11): 1036-47
• Dienstmann R, Serpico D, Rodón J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Pérez-García J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernandez-Losa J, Vivancos A, Tabernero J. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 2012 Sep; 11(9): 2062-71
• Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, Tabernero J. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012 Jun; 9(6): 359-66
• Argiles G, Rodón J, Tabernero J. Depicting the evolving scenario of translational-guided drug development. Clin Transl Oncol 2012 Dec; 14(12): 881-2
• Calvo E, Vermorken JB, Hiret S, Rodón J, Cortes J, Senellart H, Van den Brande J, Dyck J, Pétain A, Ferre P, Bennouna J. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. Cancer Chemother. Pharmacol. 2012 Jun; 69(6): 1467-75
• Rodón J, Jacobs CD, Chu Q, Rowinsky EK, Lopez-Anaya A, Takimoto CH, Wakelee HA. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Cancer Chemother. Pharmacol. 2012 Mar; 69(3): 825-34 Serrano C, Morales R, Suárez C, Nuñez I, Valverde C, Rodón J, Humbert J, Padrós O, Carles J. Emerging therapies for urothelial cancer. Cancer Treat. Rev. 2012 Jun; 38(4): 311-7
• Bendell JC, Rodón J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2012 Jan; 30(3): 282-90
• Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodón J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2011 Oct; 17(19): 6304-12
• Dienstmann R, Rodón J, Markman B, Tabernero J. Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer Drug Discov 2011 May; 6(2): 210-36
• Dienstmann R, Braña I, Rodón J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011; 16(12): 1729-40
• Huang HJ, Angelo LS, Rodón J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing’s sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS ONE 2011; 6(10): e26060
• Morales-Barrera R, Valverde C, Rodón J, Pérez J, Maldonado X, Suárez C, Trilla E, Carles J. Bilateral testicular germ cell tumours: a single hospital experience. Clin Transl Oncol 2010 Apr; 12(4): 299-302
• Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.Cancer Cell 2010 Dec; 18(6): 655-68
• Pérez-García J, Morales R, Valverde CM, Rodón J, Suárez C, Semidey ME, Garcia-Patos V, Bartralot R, Serra M, Carles J. Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment. Ann. Oncol. 2010 Apr; 21(4): 907
• Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol 2010 Jan; 12(1): 15-21
• Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities. Eur. J. Cancer 2009 Sep; 45 Suppl 1: 309-17
• Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodón J, Mays T, Yeh IT, O’Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2009 May; 63(6): 1065-71
• Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodón J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 2009 Dec; 27(34): 5800-7
• Rodón J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 2009 Jan; 18(1): 31-43
• Martínez P, Valverde C, Morales R, Rodón J, Suárez C, Baselga J, Carles J. Docetaxel activity in second line treatment for urothelial carcinoma: a retrospective analysis European Journal of Cancer Supplements 2009 September; 7(2): 448